Navigation Links
Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
Date:8/31/2009

nt (SPA), pending commencement. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: There can be no assurance that the Company will complete cost-effective clinical trials or meet the projected development timelines for the drug candidates in its pipeline, including KRX-0401 and Zerenex; that the Company will be able to raise additional capital in the future in order to fund its operations; or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
2. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
3. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
4. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
6. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
7. Keryx Biopharmaceuticals Receives Nasdaq Notification
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
9. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... The ... (ICC) announce an agreement to collaborate across a wide range of initiatives ... building code knowledge among architects. , “Our combined membership, consisting of practicing design ...
(Date:8/2/2015)... ... August 03, 2015 , ... A new Phase I research study is ... study is led by Kenneth G. Lucas, M.D. , chief of the division ... with colleagues at Kosair Children’s Hospital and in the UofL Department ...
(Date:8/1/2015)... (PRWEB) , ... August 02, 2015 , ... AlignLife ... which will help the continuity of care for patients at this natural health care ... the unknown," Clinic Director Mary Heal said. "Heather's role is vital to our approach ...
(Date:8/1/2015)... ... 01, 2015 , ... The condition where veins are enlarged and gnarled is ... pain and discomfort. Those who spend a lot of time on their feet and ... is doing what it can to create awareness and provide a cure in observance ...
(Date:8/1/2015)... Greenwich, CT (PRWEB) , ... August 01, 2015 ... ... Great Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy ... incorporating it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier ...
Breaking Medicine News(10 mins):Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:New Patient Advocate Enhances Natural Health Care 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2
... Ben-Gurion University of the Negev researcher has achieved a ... mouse cells. "This study may open new therapeutic ... pre-pubertal cancer patients at risk of infertility due to ... in adult patients," explains Prof. Mahmoud Huleihel, of BGU,s ...
... Training basic surgical techniques on toy animals before having to ... anxious. At the same time, the use of laboratory animals ... from LIFE - the Faculty of Life Sciences at the ... known as the ,teddy laboratory, strengthens learning and the teaching ...
... Amanda Gardner HealthDay Reporter , MONDAY, Nov. 14 ... of the brain seem to be involved in "chemo brain," ... treatments for breast cancer. According to research in the ... areas of the brain that are involved in planning, attention ...
... 15 (HealthDay News) -- Brainy children are at increased risk ... study says. Researchers analyzed data from nearly 8,000 people ... education and socioeconomic status. The participants, IQ scores were checked ... illegal drugs (marijuana, cocaine, uppers, downers, LSD and heroin) was ...
... Steven Reinberg HealthDay Reporter , TUESDAY, Nov. 15 ... to the statin drug Zocor (simvastatin) to help lower their ... Even though niacin appeared to increase HDL cholesterol -- ... fat in the blood, it did not reduce the risk ...
... breakthrough in understanding what stops a common form of skin ... available to the public in five years. ... Cancer Cell , an international team of scientists led ... University,s Department of Medicine at the Alfred Hospital, has discovered ...
Cached Medicine News:Health News:Surgery on toy animals lessens anxiety of veterinary students 2Health News:Breast Cancer Chemo Tied to Memory Troubles 2Health News:Breast Cancer Chemo Tied to Memory Troubles 3Health News:Smart Kids More Likely to Try Illicit Drugs as Young Adults 2Health News:No Benefit From Niacin for Heart Patients in Study 2Health News:No Benefit From Niacin for Heart Patients in Study 3Health News:Stop signal discovered for skin cancer 2
(Date:7/31/2015)... July 31, 2015 The Physician-Patient Alliance ... on July 28, 2015, "Surviving Your Hospital Stay: ... for Patient Safety." A sentence was ... read: "PPAHS is a member of ... Opioids. For more information on the National Coalition to ...
(Date:7/31/2015)...  Xcelience, a contract development and manufacturing organization ... structured cash investment in Powdersize, a ... and powder size classification within the pharmaceutical industry.  ... simultaneously adding a complete set of particle size ... "As we continue to build our ...
(Date:7/31/2015)... PORTLAND, Ore., July 31, 2015  Semler Scientific, Inc. ... and testing services to healthcare insurers and physician groups, ... June 30, 2015. "In the second ... over year revenue growth of 54%, quarter over quarter ... of the installed base of FloChec® units of 18%," ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
... SAN DIEGO, Jan. 19, 2012 Sequenom, Inc. (NASDAQ: SQNM ... to market and other conditions, shares of its common stock in ... whether or when the offering may be completed, or as to ... & Company, Inc. is acting as sole book-running manager for the ...
... 19, 2012 Medicare officials should swiftly authorize a Special ... Medicare Part D prescription drug plan if the patient believes ... "preferred network" plan with inadequate pharmacy access, the National ... the start of the 2012 plan year on January 1, ...
Cached Medicine Technology:Sequenom Announces Proposed Public Offering of Common Stock 2Pharmacists Ask Medicare to Help Seniors Complaining About Inadequate Pharmacy Access in Medicare Prescription Drug Plans 2Pharmacists Ask Medicare to Help Seniors Complaining About Inadequate Pharmacy Access in Medicare Prescription Drug Plans 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: